Kryptos Biotechnologies: Illuminating the Path to Faster Diagnostics
April 9, 2024, 9:34 pm
Location: United States, California, Hayward
Employees: 11-50
Founded date: 2017
Total raised: $10M
Kryptos Biotechnologies, a rising star in the biotech world, recently secured $10 million in Series A funding to propel their innovative molecular diagnostics system towards FDA approval by 2025. Led by CEO Jinyong Lee, this Hayward-based company is revolutionizing the field with their cutting-edge technology that harnesses light to generate heat and control temperature.
Kryptos Biotechnologies' flagship product, the KuickTM system, is a game-changer in the realm of point-of-care molecular diagnostics. By utilizing their unique Photothermal Heating technology, Kryptos has developed Ultrafast Photonic PCR, a rapid testing method that delivers accurate results in just 20 minutes. This breakthrough has the potential to transform the way clinicians make treatment decisions, providing them with timely and precise information to guide patient care.
The partnership with Osang Healthcare, a renowned medical device company, not only brings in crucial funding but also opens up avenues for manufacturing and distribution of Kryptos' groundbreaking product. This strategic collaboration underscores the industry's recognition of Kryptos Biotechnologies' potential to meet the growing demand for fast and reliable molecular diagnostics on a global scale.
In a world where speed and accuracy are paramount, Kryptos Biotechnologies is at the forefront of innovation, paving the way for decentralized clinics to access state-of-the-art diagnostic tools. With the KuickTM system, the days of waiting 1-3 days for test results are numbered, as this revolutionary technology aims to deliver actionable insights in a fraction of the time.
As the healthcare landscape continues to evolve, Kryptos Biotechnologies stands out as a beacon of progress, offering a glimpse into a future where diagnostics are not just efficient but also accessible to all. With their unwavering commitment to advancing the field of molecular diagnostics, Kryptos Biotechnologies is poised to make a lasting impact on the way we approach healthcare.
Kryptos Biotechnologies' flagship product, the KuickTM system, is a game-changer in the realm of point-of-care molecular diagnostics. By utilizing their unique Photothermal Heating technology, Kryptos has developed Ultrafast Photonic PCR, a rapid testing method that delivers accurate results in just 20 minutes. This breakthrough has the potential to transform the way clinicians make treatment decisions, providing them with timely and precise information to guide patient care.
The partnership with Osang Healthcare, a renowned medical device company, not only brings in crucial funding but also opens up avenues for manufacturing and distribution of Kryptos' groundbreaking product. This strategic collaboration underscores the industry's recognition of Kryptos Biotechnologies' potential to meet the growing demand for fast and reliable molecular diagnostics on a global scale.
In a world where speed and accuracy are paramount, Kryptos Biotechnologies is at the forefront of innovation, paving the way for decentralized clinics to access state-of-the-art diagnostic tools. With the KuickTM system, the days of waiting 1-3 days for test results are numbered, as this revolutionary technology aims to deliver actionable insights in a fraction of the time.
As the healthcare landscape continues to evolve, Kryptos Biotechnologies stands out as a beacon of progress, offering a glimpse into a future where diagnostics are not just efficient but also accessible to all. With their unwavering commitment to advancing the field of molecular diagnostics, Kryptos Biotechnologies is poised to make a lasting impact on the way we approach healthcare.